Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. CRSP
stocks logo

CRSP

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Intellectia AI SwingMax
Intellectia AI SwingMax

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
3.87M
-89.16%
-1.225
+178.45%
2.58M
+197.87%
-1.092
-30.91%
4.10M
+360.08%
-1.138
-11.74%
Estimates Revision
The market is revising No Change the revenue expectations for CRISPR Therapeutics AG (CRSP) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 6.05%.
Revenue Estimates for FY2025
No Change
down Image
0.00%
In Past 3 Month
EPS Estimates for FY2025
No Change
down Image
0.00%
In Past 3 Month
Stock Price
Go Up
up Image
+6.05%
In Past 3 Month
Wall Street analysts forecast CRSP stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CRSP is 73.41 USD with a low forecast of 40.00 USD and a high forecast of 105.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
20 Analyst Rating
Wall Street analysts forecast CRSP stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CRSP is 73.41 USD with a low forecast of 40.00 USD and a high forecast of 105.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
13 Buy
7 Hold
0 Sell
Moderate Buy
Current: 58.180
sliders
Low
40.00
Averages
73.41
High
105.00
Current: 58.180
sliders
Low
40.00
Averages
73.41
High
105.00
Chardan
Buy
downgrade
$82 -> $74
2025-11-26
Reason
Chardan
Price Target
$82 -> $74
2025-11-26
downgrade
Buy
Reason
Chardan lowered the firm's price target on Crispr Therapeutics to $74 from $82 and keeps a Buy rating on the shares. The firm updated the company's model post the Q3 report.
Citi
Yigal Nochomovitz
Buy
downgrade
$87 -> $77
2025-11-12
Reason
Citi
Yigal Nochomovitz
Price Target
$87 -> $77
2025-11-12
downgrade
Buy
Reason
Citi analyst Yigal Nochomovitz lowered the firm's price target on Crispr Therapeutics to $77 from $87 and keeps a Buy rating on the shares.
JPMorgan
Brian Cheng
Overweight
downgrade
$70 -> $69
2025-11-11
Reason
JPMorgan
Brian Cheng
Price Target
$70 -> $69
2025-11-11
downgrade
Overweight
Reason
JPMorgan analyst Brian Cheng lowered the firm's price target on Crispr Therapeutics to $69 from $70 and keeps an Overweight rating on the shares. The firm views the company's Q3 report as inline.
Baird
Neutral
downgrade
$52 -> $44
2025-11-11
Reason
Baird
Price Target
$52 -> $44
2025-11-11
downgrade
Neutral
Reason
Baird lowered the firm's price target on Crispr Therapeutics to $44 from $52 and keeps a Neutral rating on the shares. The firm updated its model following Q3 results which met expectations but where Casgevy represents a potential headwind.
RBC Capital
Sector Perform
maintain
$42 -> $50
2025-11-11
Reason
RBC Capital
Price Target
$42 -> $50
2025-11-11
maintain
Sector Perform
Reason
RBC Capital raised the firm's price target on Crispr Therapeutics to $50 from $42 and keeps a Sector Perform rating on the shares after its better than expected Q3 earnings. The firm "appreciate all the progress" but still remains on the sidelines with a cautious stance on Casgevy's launch and pending further progress on the rest of the pipeline, the analyst tells investors in a research note.
Clear Street
Hold
downgrade
$52 -> $50
2025-11-10
Reason
Clear Street
Price Target
$52 -> $50
2025-11-10
downgrade
Hold
Reason
Clear Street lowered the firm's price target on Crispr Therapeutics to $50 from $52 and keeps a Hold rating on the shares. Crispr is trading even after reporting Q3 results, which showed a smaller loss than anticipated on lower R&D spend than expected, the analyst tells investors in a research note. The firm noted that Casgevy continued its slow initial launch, resulting in $57M in associated collaboration expense for the quarter, adding that it awaits either a clearer inflection point for Casgevy or for high-potential pipeline assets to show clinical data that increase confidence in their likelihood of success.
See All Ratings

Valuation Metrics

The current forward P/E ratio for CRISPR Therapeutics AG (CRSP.O) is -12.99, compared to its 5-year average forward P/E of -13.25. For a more detailed relative valuation and DCF analysis to assess CRISPR Therapeutics AG 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-13.25
Current PE
-12.99
Overvalued PE
10.72
Undervalued PE
-37.22

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-8.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
8.80
Undervalued EV/EBITDA
-24.80

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
256.07
Current PS
0.00
Overvalued PS
650.02
Undervalued PS
-137.89
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
N/A
ROIC

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders areSelling! The selling amount has increased 400.94% over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders areSelling! The selling amount has increased 400.94% over the last month.
Sold
Bought
AI Stock Picker
AI Stock Picker

CRSP News & Events

Events Timeline

(ET)
2025-12-01
10:20:00
Crispr Therapeutics Rumor Causes 1% Drop in Shares
select
2025-11-17 (ET)
2025-11-17
10:59:17
Rumors About Crispr Therapeutics Featured in Betaville Blog
select
2025-11-11 (ET)
2025-11-11
16:27:07
Richard Pazdur Named Director of CDER by FDA
select
link
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
8.0
12-04NASDAQ.COM
Noteworthy CRSP Put and Call Options Set for January 2026

  • Put Contract Overview: The $46.00 put contract has a bid of $1.00, allowing investors to buy CRSP shares at a cost basis of $45.00, which is a 19% discount from the current price of $57.01. There is a 78% chance the contract may expire worthless, offering a potential 2.17% return on cash commitment.

  • Call Contract Overview: The $58.00 call contract has a bid of $2.45, enabling investors to sell CRSP shares at that price if they buy at $57.01. This could yield a 6.03% return if exercised, with a 52% chance of expiring worthless, which would provide a 4.30% additional return.

  • Volatility Insights: The implied volatility for the put contract is 78%, while the call contract's implied volatility is 67%. The actual trailing twelve-month volatility is calculated at 62%.

  • YieldBoost Concept: The article discusses the concept of YieldBoost, highlighting potential returns from both put and call contracts, and encourages investors to track these options and their changing odds on Stock Options Channel's website.

[object Object]
Preview
8.5
12-01SeekingAlpha
Crispr Therapeutics Reduces Losses Amid Acquisition Rumors

  • Takeover Speculation: Crispr Therapeutics (CRSP) is experiencing speculation regarding a potential takeover, with reports indicating that a buyer has engaged an adviser for the bid.

  • Market Interest: A US-based biopharma company, valued between $100-$200 billion, is rumored to be interested in acquiring Crispr Therapeutics, as noted in a recent Betaville alert.

[object Object]
Preview
5.0
11-25TipRanks
Cathie Wood Reinforces Investment in This AI Stock, Reduces Stake in GitLab (GTLB) Once More

  • ARK Invest's New Trades: On November 24, ARK Invest reported significant buying activity in CoreWeave, CRISPR Therapeutics, and crypto-related stocks, while reducing its stakes in GitLab, Reddit, Iridium Communications, and Ibotta.

  • CoreWeave Investment: ARK made a notable purchase of 437,345 shares of CoreWeave, valued at approximately $31.3 million, continuing a trend of consistent buying despite the stock's recent decline of about 44%.

  • Biotech and Crypto Exposure: The firm also increased its investment in CRISPR Therapeutics by acquiring 42,404 shares worth around $2.1 million, and added to its crypto holdings with purchases in Circle Internet and Bullish.

  • GitLab Position Reduction: ARK further decreased its position in GitLab, selling 646,911 shares valued at about $26.8 million, indicating a strategic move to gradually exit the stock.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is CRISPR Therapeutics AG (CRSP) stock price today?

The current price of CRSP is 58.18 USD — it has increased 3.91 % in the last trading day.

arrow icon

What is CRISPR Therapeutics AG (CRSP)'s business?

CRISPR Therapeutics AG is a Switzerland-based gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) and is a technology for gene editing, the process of precisely altering specific sequences of genomic DNA. The Company aims to apply this technology to disrupt, delete, correct and insert genes to treat genetically-defined diseases and to engineer advanced cellular therapies. The Company has acquired the rights to the intellectual property (IP) encompassing CRISPR/Cas9 and related technologies and is also involved in its own IP research and additional in-licensing efforts. The Company product development and partnership strategies are designed to exploit the full potential of the CRISPR/Cas9 platform while maximizing the probability of successfully developing their product candidates.

arrow icon

What is the price predicton of CRSP Stock?

Wall Street analysts forecast CRSP stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CRSP is 73.41 USD with a low forecast of 40.00 USD and a high forecast of 105.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is CRISPR Therapeutics AG (CRSP)'s revenue for the last quarter?

CRISPR Therapeutics AG revenue for the last quarter amounts to 889.00K USD, increased 47.67 % YoY.

arrow icon

What is CRISPR Therapeutics AG (CRSP)'s earnings per share (EPS) for the last quarter?

CRISPR Therapeutics AG. EPS for the last quarter amounts to -1.17 USD, increased 15.84 % YoY.

arrow icon

What changes have occurred in the market's expectations for CRISPR Therapeutics AG (CRSP)'s fundamentals?

The market is revising No Change the revenue expectations for CRISPR Therapeutics AG (CRSP) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 6.05%.
arrow icon

How many employees does CRISPR Therapeutics AG (CRSP). have?

CRISPR Therapeutics AG (CRSP) has 393 emplpoyees as of December 05 2025.

arrow icon

What is CRISPR Therapeutics AG (CRSP) market cap?

Today CRSP has the market capitalization of 5.54B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free